Department of Pediatrics, Division of Rheumatology, The University of Alabama at Birmingham, Children's Park Place 210, 1600 7th Ave South, Birmingham, AL 35233, USA.
Curr Rheumatol Rep. 2013 May;15(5):327. doi: 10.1007/s11926-013-0327-1.
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease of childhood. Many questions regarding the risk of infection associated with JIA and with the immunosuppressant therapeutic agents commonly used to treat JIA are currently unanswered. It appears likely that JIA itself increases the background rate of serious bacterial infections, irrespective of immunosuppressant use. The available evidence suggests that treatment with methotrexate or tumor necrosis factor inhibitors only modestly increases the risk of serious infections and may not increase the risk at all. Opportunistic infections are very uncommon among children with JIA, but they likely occur at an increased rate compared to children without JIA. Intra-articular glucocorticoid injections almost never result in infectious complications in the treatment of JIA when performed carefully. Additional controlled studies of the risks of infection among children with JIA are needed, particularly comparative studies of newer therapeutic agents.
幼年特发性关节炎(JIA)是儿童最常见的风湿性疾病。目前,仍有许多关于 JIA 相关感染风险以及常用于治疗 JIA 的免疫抑制剂治疗药物的问题尚未得到解答。似乎 JIA 本身会增加严重细菌感染的背景发生率,而与免疫抑制剂的使用无关。现有证据表明,使用甲氨蝶呤或肿瘤坏死因子抑制剂治疗仅会适度增加严重感染的风险,而实际上可能根本不会增加风险。机会性感染在 JIA 患儿中非常罕见,但与无 JIA 患儿相比,其发生风险可能更高。在 JIA 治疗中,仔细进行关节内糖皮质激素注射几乎不会导致感染并发症。需要对 JIA 患儿的感染风险进行更多的对照研究,特别是对新型治疗药物的比较研究。